¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Receptors, Tumor Necrosis Factor, Type II"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • organic reaction type
    ±âÁú¹ÝÀÀÇü
  • ovulatory type
    ¹è¶õÇü
  • polymyarian type
    ´Ù±ÙÀ°Çü
  • precision type attachment
    Á¤¹ÐÇüºÎÂø
  • propagative type
    Áõ½ÄÇü
  • pyknic body type
    ´Ü½Åºñ¸¸½ÅüÇü
  • parthenogenetic type
    ´Ü¼º»ý½ÄÇü
  • split-electrode-type probe
    ºÐÇÒÀü±Ø´õµëÀÚ
  • sthenic type
    ±Ù·ÂÇü
  • storage-type
    ÃàÀûÇü
  • swaged cast type crown
    ¾ÐÀÎÇü±Ý°ü
  • sympathicotonic type
    ±³°¨½Å°æ±äÀåÇü
  • simple type schizophrenia
    ´Ü¼øÇüÁ¤½ÅºÐ¿­º´
  • viral hepatitis type A
    AÇü¹ÙÀÌ·¯½º°£¿°
  • viral hepatitis type B
    BÇü¹ÙÀÌ·¯½º°£¿°
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • granulosa cell tumor
    °ú¸³Ãþ¼¼Æ÷Á¾¾ç
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • mesenchymal tumor
    Áß°£¿±Á¾¾ç
  • metastatic tumor
    ÀüÀÌÁ¾¾ç
  • neuroepithelial tumor
    ½Å°æ»óÇÇÁ¾¾ç
  • nonfunctioning tumor
    ºñ±â´ÉÁ¾¾ç
  • occult primary tumor
    Àẹ¿ø¹ßÁ¾¾ç
  • odontogenic tumor
    Ä¡¾ÆÅ¿Á¾¾ç, Ä¡¿øÁ¾¾ç
  • peripheral primitive neuroectodermal tumor
    ¸»ÃÊ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
  • phyllodes tumor
    ¿±»óÁ¾¾ç
  • primitive neuroectodermal tumor
    ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
  • renin-secreting juxtaglomerular tumor
    ·¹´ÑºÐºñÅ丮°çÁ¾¾ç, ·¹´ÑºÐºñ»ç±¸Ã¼¿·Á¾¾ç
  • Sertoli-Leydig tumor
    ¼¼¸£Å縮¶óÀ̵ðÈ÷ Á¾¾ç
  • smooth muscle tumor
    ÆòȰ±ÙÁ¾¾ç
  • solid tumor
    °íÇüÁ¾¾ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • holomyarian type
    ¿ÏÀü±ÙÀ°Çü
  • hypertrophic type
    ºñ´ëÇü
  • tuberculin-type hypersensitivity
    (¢¡delayed-type hypersensitivity) Áö¿¬°ú¹Î
  • introversion type
    ³»ÇâÇü
  • intuitive type
    Á÷°üÇü
  • lepromatous type
    ³ªº´Á¾Çü
  • leptosomatic type
    ¸¶¸¥Çü
  • mating type
    ±³¹èÇü
  • meromyarian type
    ºÎºÐ±ÙÀ°Çü
  • plaque-type mutation
    ÇöóÅ©Çüµ¹¿¬º¯ÀÌ
  • nomenclatural type
    ºÐ·ùÇÐÀû±âÁظí
  • organic reaction type
    ±âÁú¹ÝÀÀÇü
  • ovulatory type
    ¹è¶õÇü
  • parthenogenetic type
    ´Ü¼º»ý½ÄÇü
  • polymyarian type
    ´Ù±ÙÀ°Çü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • antigen, tumor-specific transplantation
    Á¾¾çƯÀÌ À̽ÄÇ׿ø
  • antigen,fetal tumor-associated
    žÆÁ¾¾ç °ü·Ã¼º(÷Ãä®ðþåË Î¼Ö¤àõ)
  • antigen,tumor-specific transplantation
    Á¾¾ç ƯÀÌÀ̽Ä(ðþåË ÷åì¶ì¹ãÕ)
  • appendigeal tumor
    ºÎ¼Ó±â Á¾¾ç(ðþåË)
  • genitourinary tumor
    ºñ´¢»ý½Ä±â Á¾¾ç
  • germ cell tumor
    »ý½Ä¼¼Æ÷Á¾(ßæãÖá¬øàðþ)
  • giant cell tumor
    °Å¼¼Æ÷Á¾¾ç.
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾¾ç.(¡­ðþåË)
  • glomus jugulare tumor
    °æÁ¤¸Æ±¸Á¾¾ç
  • glomus tumor<³ª>
    »ç±¸Á¾¾ç, ±Û·Î¹«½ºÁ¾¾ç(¡­ðþåË)
  • glomus tumor<³ª>
    »ç±¸Á¾, ±Û·Î¹«½ºÁ¾¾ç(¡­ðþåË)
  • gonadal stromal tumor
    ¼º¼±°£ÁúÁ¾¾ç
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç.
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • liver cell necrosis
    °£¼¼Æ÷ ±«»ç(¡­ÎÕÞÝ)
  • liver necrosis
    °£±«»ç.
  • liver,central hemorrhagic necrosis
    Á᫐ ÃâÇ÷¼º ±«»ç(ñéãý õóúìàõ ¡­)
  • liver,centrilobular necrosis
    ¼Ò¿± Á߽ɼº ±«»ç(á³ç¨ ¡­)
  • liver,submassive-to-massive necrosis
    ±¤¹ü¼º ±«»ç(ÎÆÛôàõ ¡­)
  • massive hepatic necrosis
    ±¤¹ü¼º °£±«»ç.
  • massive hepatic necrosis
    ±¤¹ü¼º °£±«»ç(ÎÆÛôàõ ÊÜÎÕÞÝ)
  • medial necrosis
    ÁßÃþ±«»ç(ñéöµÎÕÞÝ) ¡ìµ¿¸Æ±Ù Ãþ(ÔÑØæÐÉöµ)±«»ç¡í.
  • medial necrosis
    ÁßÃþ±«»ç(ñéöµÎÕÞÝ) ¡ìµ¿¸Æ±Ù Ãþ(ÔÑØæÐÉöµ)±«»ç¡í
  • mummification necrosis
    ¹ÌÀ̶óÈ­±«»ç(¡­ûùÎÕÞÝ)
  • myocardial necrosis
    ½É±Ù±«»ç(¡­ÎÕÞÝ).
  • necrosis
    񮯇
  • necrosis
    񮯇
  • nodular fat necrosis
    °áÀý¼º Áö¹æ ±«»ç
  • nodular fat necrosis
    °áÀý¼º Áö¹æ±«»ç(¡­ò·Û¸ÎÕÞÝ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • antispecificity factor
    Çׯ¯À̼º ÀÎÀÚ(ù÷÷åì¶àõì×í­)
  • antisterility factor
    Ç׺ÒÀÓ ÀÎÀÚ(ù÷ÝÕìõì×í­)
  • antitermination factor
    Ç×Á¾·á ÀÎÀÚ(ù÷ðûÖõì×í­)
  • antixerophthalmic factor
    Ç׾ȱ¸ °ÇÁ¶Áõ ÀÎÀÚ(ù÷äÑϹËëðÏñøì×í­)
  • Arrenius factor
    ¾Æ·¹´Ï¿ì½º ÀÎÀÚ(ì×í­)
  • asymmetry factor
    ºñ±¸»ó ÀÎÀÚ (ުϹßÒì×í­)
  • atrial natriuretic factor
    ½É¹æ(ãýÛ®) ³ªÆ®·ý¹è¼³ÀÎÀÚ(ÛÉàÜì×í­)
  • bacteriocin factor
    "¹ÚÅ׸®¿À½Å ÀÎÀÚ(ì×í­), »ì±ÕÀÎÀÚ(߯жì×í­)"
  • binding factor
    °áÇÕÀÎÀÚ(Ì¿ùêì×í­)
  • calcium-activated factor
    Ä®½·ºÎȰ ÀÎÀÚ(Ý·üÀì×í­)
  • cell factor
    ¼¼Æ÷ÀÎÀÚ(á¬øàì×í­)
  • chloroplast coupling factor
    ¿±·Ïü(ç¨Öàô÷) ¦ÁöÀ½ÀÎÀÚ(ì×í­)
  • Christmas factor
    Å©¸®½º¸¶½º ÀÎÀÚ(ì×í­)
  • citrovorum factor
    "½ÃÆ®·Îº¸·ë ÀÎÀÚ,"
  • clearance factor
    ûÁ¤ÀÎÀÚ(ôèïäì×í­)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • vanishing tumor
    Àϰú¼ºÁ¾¾ç»óÀ½¿µ, Àϰú¼º¿±°£Èä¼öÀú·ù(»ó)
  • Warthin's tumor
    ¿Í¸£Æ¾Á¾¾ç
  • Wilms' tumor
    Àª¸§Á¾¾ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
TNFBR tumor necrosis factor beta receptor
PAF paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl...
SF Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f...
TF free thyroxine; tactile fremitus; tail flick [reflex]; temperature factor; testicular feminization; ...
AN acanthosis nigricans; acne neonatorum; acoustic neuroma; adult, normal; ala nasi; amyl nitrate; aneu...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
PTBR Peripheral-type benzodiazepine receptors
EGFr Epithelial Growth Factor receptors
PDGFR Platelet Derived Growth Factor Receptors
VEGFR Vascular Endothelial Growth Factor Receptors
TNF alpha Anti-tumour necrosis factor alpha
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • knife edge type
    ³ªÀÌÇÁ ¿¡Âî ŸÀÔ
    finishing lineÀÇ ÀÏÁ¾ÀÌ´Ù.
  • lepromatous type
    ³ªÁ¾Çü
  • localized type
    ±¹¼ÒÇü
  • major type
    ÁÖµÈ ÇüÅÂ
  • membrane type
    ¸·Çü
  • mesial step type
    ±Ù½É °è´ÜÇü
  • mobile type diagnostic X ray apparatus
    À̵¿Çü Áø´Ü X¼± ÀåÄ¡
  • monocytic type
    ´ÜÇÙ±¸Çü
  • morphea-like type
    ¹Ý»ó °æÇÇÁõ °°Àº ÇüÅÂ
  • multifocal type
    ´Ù¹ß¼º
  • muscle tension type headache
    ±Ù ±äÀ强 µÎÅë
    ÈĵκÎ, Ç׺ÎÀÇ Áö¼ÓÀûÀÎ ¾Ð¹Ú°¨, ±³¾×°¨À» È£¼ÒÇÑ´Ù. ÀÌ ÁõÀÇ È¯ÀÚ´Â ½Å°æÁú·Î ±äÀåÇϱ⠽¬¿î »ç¶÷¿¡°Ô ¸¹°í °³Ã¼ÀÇ ±Ù±äÀ强¼ÒÀΰú ¾î¿ï¾îÁ® ±ÙÀÇ Áö¼ÓÀû ¼öÃà°ú ±ÙÀÇ ¼øÈ¯ ºÎÀü ¡æ ÅëÁõ ¹°Áú ¹ß»ý ¡æ ÅëÁõ ¡æ ±Ù ¼öÃàÀ̶ó´Â ¾Ç¼øÈ¯ÀÌ Çü¼ºµÇ´Â °ÍÀ¸·Î »ý°¢µÈ´Ù. Á÷¾÷¿¡ µû¸¥ ºÎÀÚ¿¬½º·¯¿î ÀÚ¼¼°¡ °ü·ÃÀÌ ÀÖ´Â °æ¿ìµµ ¸¹°í ½Åü, ½É¸®Àû ¾çÃø¸éÀ¸·ÎºÎÅÍÀÇ Á¢±ÙÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹´Ù.
  • muscular type of vein
    ±ÙÀ°Çü Á¤¸Æ
  • nonnecrotizing type
    ºñ±«»ç¼º ÇüÅÂ
  • oral-facial-digital syndrome, type I
    IÇü±¸-¾È¸é-ÁöÁõÈıº
    X-¿¬°ü¼º ¿ì¼º À¯Àüº´À¸·Î¼­ ³²ÀÚ¿¡°Ô´Â Ä¡¸íÀûÀ¸·Î ±¼ÁöÁõ, ´ÙÁöÁõ, ÇÕÁöÁõ µîÀÌ Æ¯Â¡À̸ç, µÎ°³, ¾È¸é, ¼³, ±¸°³ ¹× ÇÏ¾Ç ±âÇüÀ» ¼ö¹ÝÇϰųª Áö´É ÀúÇÏ, Å»¸ðÁõ, ¾È¸é Áö·ç¸¦ ¼ö¹ÝÇÑ´Ù.
  • pedunclated type
    À¯°æÇü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
focal necrosis Occurrence of numerous, relatively small or tiny, fairly well-circumscribed, usually spheroidal portions of tissue that manifest coagulative, caseous, or gummatous necrosis and are characteristically associated with agents that are haematogenously disseminated; frequently observed only in histologic sections, but the foci may be as large as 1 to 3 mm and macroscopically visible; arbitrarily, foci larger than that are usually not termed focal necrosis.
(05 Mar 2000)
laminar cortical necrosis The breaking down of a definite cell layer in the cerebral cortex, encountered typically after temporary cardiac arrest or perinatal hypoxia.
(05 Mar 2000)
liquefactive necrosis A type of necrosis characterised by a fairly well-circumscribed, microscopically or macroscopically visible lesion that consists of the dull, opaque or turbid, gray-white to yellow-gray, soft or boggy, partly or completely fluid remains of tissue that became necrotic and was digested by enzymes, especially proteolytic enzymes liberated from disintegrating leukocytes; it is classically observed in abscesses, and frequently in infarcts of the brain.
(05 Mar 2000)
adrenergic receptors Reactive components of effector tissues, most of which are innervated by adrenergic postganglionic fibres of the sympathetic nervous system. Such receptor's can be activated by norepinephrine and/or epinephrine and by various adrenergic drugs; receptor activation results in a change in effector tissue function, such as contraction of arteriolar muscles or relaxation of bronchial muscles; adrenergic receptor's are divided into alpha-receptor's and beta-receptor's, on the basis of their response to various adrenergic activating and blocking agents.
Synonym: adrenoceptor, adrenoreceptors.
(05 Mar 2000)
alpha-adrenergic receptors Adrenergic receptor's in effector tissues capable of selective activation and blockade by drugs; conceptually derived from the ability of certain agents, such as phenoxybenzamine, to block only some adrenergic receptor's and of other agents, such as methoxamine, to activate only the same adrenergic receptor's. Such receptor's are designated as alpha-receptors. Their activation results in physiological responses such as increased peripheral vascular resistance, mydriasis, and contraction of pilomotor muscles.
(05 Mar 2000)
ANP clearance receptors Cell surface proteins that bind atrial natriuretic peptide and ANP fragments without initiating biological action.
(05 Mar 2000)
ANP receptors Cell surface receptors for atrial natriuretic peptide that have a single transmembrane spanning element; these have integral kinase and guanylate cyclase domains.
(05 Mar 2000)
B-cell antigen receptors In the primary immune response immunoglobulin D and monomeric immunoglobulin M are the B-cell antigen receptors. On memory B-cells, other immunoglobulin molecules can serve as antigen receptors.
(05 Mar 2000)
beta-adrenergic receptors Adrenergic receptor's in effector tissues capable of selective activation and blockade by drugs; conceptually derived from the ability of certain agents, such as propranolol, to block only some adrenergic receptor's and of other agents, such as isoproterenol, to activate only the same adrenergic receptor's. Such receptor's are designated as beta-receptors. Their activation results in physiological responses such as increases in cardiac rate and force of contraction (b1), and relaxation of bronchial and vascular smooth muscle (b2).
(05 Mar 2000)
mannose-6-phosphate receptors Receptors in Golgi apparatus to which newly synthesised proteins that are destined to enter lysosomes bind.
(05 Mar 2000)
receptors, adrenergic Cell-surface proteins that bind epinephrine and/or norepinephrine with high affinity and trigger intracellular changes. The two major classes of adrenergic receptors, alpha and beta, were originally discriminated based on their cellular actions but now are distinguished by their relative affinity for characteristic synthetic ligands. Adrenergic receptors may also be classified according to the subtypes of g-proteins with which they bind; this scheme does not respect the alpha-beta distinction.
(12 Dec 1998)
receptors, adrenergic, alpha One of the two major pharmacological subdivisions of adrenergic receptors. The alpha-beta distinction was originally based on cellular effects of receptor activation but now relies on the relative affinities for certain synthetic ligands. Alpha-adrenergic receptors are further subdivided into several subclasses based on studies of endogenous and cloned receptors.
(12 Dec 1998)
receptors, adrenergic, alpha-1 A subclass of alpha-adrenergic receptors (receptors, adrenergic, alpha). Alpha-1 adrenergic receptors can be pharmacologically discriminated, e.g., by their high affinity for the agonist phenylephrine and the antagonist prazosin. They are widespread, with clinically important concentrations in the liver, the heart, vascular, intestinal, and genitourinary smooth muscle, and the central and peripheral nervous systems.
(12 Dec 1998)
receptors, adrenergic, alpha-2 A subclass of alpha-adrenergic receptors (receptors, adrenergic, alpha). Alpha-2 adrenergic receptors can be pharmacologically discriminated, e.g., by their high affinity for the agonist clonidine and the antagonist yohimbine. They are found on pancreatic beta cells, platelets, and vascular smooth muscle, as well as both pre- and postsynaptically in the central and peripheral nervous systems.
(12 Dec 1998)
receptors, adrenergic, beta One of the two major pharmacologically defined classes of adrenergic receptors. The alpha-beta distinction was originally based on the cellular effects of receptor activation but now relies on the relative affinities for characteristic synthetic ligands. Beta adrenergic receptors are further subdivided based on information from endogenous and cloned receptors.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á